Rabbit Polyclonal EGF Antibody

+ +

•  

   
     All lanes : Anti-EGF Antibody (Center) at  1:2000 dilution Lane 1: M.stomach tissue lysates Lane 2: A549 whole cell lysates Lysates/proteins at 20 µg per lane. Secondary Goat Anti-Rabbit IgG,  (H+L), Peroxidase conjugated at 1/10000 dilution Predicted band size : 134 kDa Blocking/Dilution buffer: 5% NFDM/TBST.    

•  

   
     P33039 staining EGF in Human kidney tissue sections by Immunohistochemistry (IHC-P - paraformaldehyde-fixed,  paraffin-embedded sections).  Tissue was fixed with formaldehyde and blocked with 3% BSA for 0. 5 hour at room temperature; antigen retrieval was by heat mediation with a citrate buffer (pH6).  Samples were incubated with primary antibody (1/25) for 1 hours at 37°C.  A undiluted biotinylated goat polyvalent antibody was used as the secondary antibody.    

•  

   
     P33039 staining EGF in Human heart tissue sections by Immunohistochemistry (IHC-P - paraformaldehyde-fixed,  paraffin-embedded sections).  Tissue was fixed with formaldehyde and blocked with 3% BSA for 0. 5 hour at room temperature; antigen retrieval was by heat mediation with a citrate buffer (pH6).  Samples were incubated with primary antibody (1/25) for 1 hours at 37°C.  A undiluted biotinylated goat polyvalent antibody was used as the secondary antibody.    

Epidermal Growth Factor (EGF) antibodies are specialized proteins designed to target and neutralize EGF, a key signaling molecule involved in cellular processes like proliferation, differentiation, and survival. EGF binds to the epidermal growth factor receptor (EGFR) on cell surfaces, activating downstream pathways such as MAPK and PI3K/AKT, which are critical in tissue development and repair. However, dysregulated EGFR signaling is implicated in various pathologies, particularly cancers, where overexpression or mutations drive uncontrolled cell growth and metastasis.

EGF antibodies are primarily developed as therapeutic or diagnostic tools. Monoclonal antibodies (e.g., cetuximab, panitumumab) block EGFR activation, inhibiting tumor progression in cancers like colorectal and head/neck carcinomas. They may also be conjugated with drugs or radioactive isotopes for targeted therapy. In research, EGF antibodies serve as detection reagents in immunoassays (ELISA, Western blot) or immunohistochemistry to study EGFR expression patterns in tissues.

Challenges include resistance mechanisms, such as EGFR mutations or alternative pathway activation, prompting the development of combination therapies with chemotherapy or other biologics. Ongoing research explores bispecific antibodies and nanobody-based designs to enhance specificity and reduce side effects. Overall, EGF antibodies represent a cornerstone in precision medicine, bridging molecular insights with clinical applications.